Alzheimer disease (AD) is a genetically heterogeneous and progressive
degenerative disorder of the brain. It affects approximately 4 million
Americans and causes more than 100,000 deaths each year, and there is
no cure. It is estimated that by the year 2020, 14 million Americans
will be affected by the disease. Although the major pathology is confi
ned to regions of the brain, some patients show an impaired sense of s
mell and selective loss of retinal ganglion cells. The biochemical pro
cesses that lead to AD are largely unknown. Genetic studies on inherit
ed AD have identified three genes that when mutated can cause an early
-onset form of the disease. Mutation of these genes has been shown to
increase the production of a unique protein called beta-amyloid, which
is the predominant component of neuritic plaques found in the brain o
f AD patients. Also, one susceptibility gene has been shown to be asso
ciated with the risk of late-onset AD in both familial and sporadic fo
rms. The available data support to a large extent the amyloid cascade
hypothesis as a mechanism of the disease pathology. The newly identifi
ed ''AMY plaques'' and the future identification of other susceptibili
ty genes may give further clues to the neurodegenerative mechanisms of
AD.